Los Angeles, California, USA, September 3, 2026
Armata Pharmaceuticals, Inc. has announced the publication of new research providing detailed insights into the structural biology and infection mechanism of Ar-KM, a therapeutic phiKMV-like bacteriophage targeting Pseudomonas aeruginosa. Published in the peer-reviewed Journal of Molecular Biology, the study, titled “Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage,” uses cryo-electron microscopy, proteomics and bioinformatics to develop an integrative structural atlas of the phage. Researchers captured three distinct structural states from a single purified preparation and developed atomic models for 11 structural proteins at near-atomic resolution. The findings provide new information about how Ar-KM maintains its genome in a stable, packaged state before infection and then undergoes coordinated structural changes that enable genome delivery into bacterial cells.
Armata Maps Ar-KM Phage Structure and Genome Delivery
The research addresses fundamental biological mechanisms that are important for developing bacteriophage-based therapeutics. Ar-KM is designed to target P. aeruginosa, a bacterial pathogen associated with difficult-to-treat respiratory infections and a major focus of Armata’s AP-PA02 program. The structural analysis showed how the phage securely packages its genetic material before encountering a bacterial host and subsequently transitions into an infection state. Researchers also identified an enzymatic activity that helps the phage penetrate the bacterial cell envelope, an important step in initiating infection. In addition, the study characterized a previously unrecognized protein involved in the coordinated release and delivery of the phage genome. These observations connect phage structure with biological characteristics such as stability, infectivity and efficient genome delivery, which are important considerations for therapeutic phage development. The use of cryo-electron microscopy was particularly important for resolving the molecular architecture of Ar-KM. Combined with comparative genomic and mass-spectrometry approaches, the technology enabled researchers to examine the phage at near-atomic resolution. Studying different structural states also provided a view of the changes that occur as the bacteriophage moves from a stable particle to an actively infecting agent. According to the research team, this helps explain how Ar-KM can remain stable before reaching its bacterial target while rapidly mobilizing its genome once infection begins. Such mechanistic understanding may help researchers evaluate and optimize characteristics relevant to future phage therapeutic candidates.
Ar-KM Research Supports AP-PA02 Development
The publication has direct relevance to Armata’s AP-PA02 program, an inhaled bacteriophage product candidate targeting chronic pulmonary P. aeruginosa infection. AP-PA02 has completed Phase 2 clinical studies in patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB) who have chronic pulmonary P. aeruginosa infections. Armata is developing pathogen-specific bacteriophage therapies as potential alternatives or complements to conventional antibacterial approaches, particularly for infections involving antibiotic-resistant and difficult-to-treat bacteria. The company said the new publication represents the fourth publication from its collaboration with researchers led by Dr. Gino Cingolani, and the fourth study characterizing its P. aeruginosa phages. Armata also plans to extend the structural biology work to cryogenic electron microscopy reconstruction of proprietary Staphylococcus aureus phages, expanding the application of its analytical capabilities across its antibacterial pipeline. The company believes that high-quality purified phage preparations and detailed structural characterization can support deeper understanding of phage mechanisms and contribute to rational development of differentiated therapies.
Advertisement
Armata Strengthens Next-Generation Antibacterial Pipeline
The findings arrive as antimicrobial resistance continues to create demand for new approaches against bacterial infections. Unlike conventional antibiotics that generally act through defined biochemical targets, bacteriophages are viruses that specifically infect and destroy susceptible bacterial cells. Armata’s development strategy focuses on pathogen-specific phage therapeutics, including programs directed against P. aeruginosa and Staphylococcus aureus. The company has also developed in-house phage-specific cGMP manufacturing capabilities, supporting its broader objective of taking bacteriophage candidates from laboratory research through clinical development and potentially toward commercialization. For the broader field of phage therapy, the Ar-KM study demonstrates how structural biology can complement clinical development by clarifying the molecular mechanisms that govern therapeutic phage behavior. Understanding genome packaging, bacterial-cell penetration and genome ejection could help researchers assess properties that influence phage performance and therapeutic potential. While the new publication does not itself establish clinical efficacy, it provides mechanistic evidence supporting continued development of Armata’s phage platform. As the company advances its clinical programs and expands structural studies to additional pathogens, this research may contribute to the development of next-generation antibacterials for antibiotic-resistant infections.
Source: Armata Pharmaceuticals press release
